Selectively substituted quinoline compounds
US9663486B2 · kind B2 · utility
1Cited by
74References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 14, 2014 |
| Grant date | May 30, 2017 |
| Priority date | — |
| Expiry date | Oct 14, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.